Platinum-based chemotherapy is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum- based chemotherapy remain unclear. In this study, we used a proteomic approach to discover potential protein factors that are key to cause drug resistance in ovarian cancer cells. We found more than 90 proteins showed significant expression changes when two pairs of ovarian cancer cell lines, A2780/A2780-CP (cisplatin-sensitive/cisplatin-resistant) and 2008/2008-C13*5.25 (cisplatin-sensitive/cisplatin-resistant), were compared. Bio- informatics analysis suggested that several potential pathways may be involved in the platinum resistance. Our data suggest that targeting SOD1 can potentially lead to sensitization of platinum-resistant ovarian cancer cells, and SOD1 may be used as a therapeutic target for chemosensitization of ovarian cancer.
- Time: 13:30-14:30
- Date: Tuesday, September 25, 2018
- Venue: SA136
- Speaker: Prof. Mu Wang (Department of Biological Sciences, XJTLU)
Professor Mu Wang
Prof. Wang, the Head of Biological Sciences, received his PhD in Bio-organic Chemistry from Washington Univ in St.Louis, USA and was an NIH postdoc fellow. His research centers around mechanistic study of drug resistance in cancer, DNA repair mechanisms in mammalian systems in response to genomic stresses, and clinical biomarker development. Prof. Wang is a world-class proteomics expert, with more than 100 peer-reviewed articles and book chapters. He was a recipient of the HUPO (Human Proteome Organization) 2004 Young Investigator Award.